These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9920102)

  • 1. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype.
    Liu RY; Zhou JN; van Heerikhuize J; Hofman MA; Swaab DF
    J Clin Endocrinol Metab; 1999 Jan; 84(1):323-7. PubMed ID: 9920102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease.
    Wu YH; Swaab DF
    Sleep Med; 2007 Sep; 8(6):623-36. PubMed ID: 17383938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
    Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
    Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid.
    Swaab DF; Raadsheer FC; Endert E; Hofman MA; Kamphorst W; Ravid R
    J Neuroendocrinol; 1994 Dec; 6(6):681-7. PubMed ID: 7894471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human pineal gland and melatonin in aging and Alzheimer's disease.
    Wu YH; Swaab DF
    J Pineal Res; 2005 Apr; 38(3):145-52. PubMed ID: 15725334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.
    Wu YH; Feenstra MG; Zhou JN; Liu RY; Toranõ JS; Van Kan HJ; Fischer DF; Ravid R; Swaab DF
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5898-906. PubMed ID: 14671188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
    Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
    Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
    Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
    Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels.
    Zhou JN; Liu RY; Kamphorst W; Hofman MA; Swaab DF
    J Pineal Res; 2003 Sep; 35(2):125-30. PubMed ID: 12887656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
    Nitsch RM; Rebeck GW; Deng M; Richardson UI; Tennis M; Schenk DB; Vigo-Pelfrey C; Lieberburg I; Wurtman RJ; Hyman BT
    Ann Neurol; 1995 Apr; 37(4):512-8. PubMed ID: 7717688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.
    Raygani AV; Zahrai M; Raygani AV; Doosti M; Javadi E; Rezaei M; Pourmotabbed T
    Neurosci Lett; 2005 Feb; 375(1):1-6. PubMed ID: 15664112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.
    Craft S; Peskind E; Schwartz MW; Schellenberg GD; Raskind M; Porte D
    Neurology; 1998 Jan; 50(1):164-8. PubMed ID: 9443474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
    Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
    Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.
    de la Monte SM; Volicer L; Hauser SL; Wands JR
    Ann Neurol; 1992 Dec; 32(6):733-42. PubMed ID: 1471863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
    Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
    Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.